Related Experiment Videos
HMG CoA reductase inhibitors. Current clinical experience
1Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey.
Drugs
|January 1, 1988
Summary
Lovastatin and simvastatin, HMG CoA reductase inhibitors, effectively lower cholesterol over 30% and LDL-cholesterol 40%. These well-tolerated drugs show good safety profiles in extensive clinical use.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Lovastatin and simvastatin are leading HMG CoA reductase inhibitors used to treat hypercholesterolemia.
- Extensive clinical data exists for both agents, with lovastatin used for over 6 months in the US and long-term patient treatment data available for both.
Purpose of the Study:
- To review the efficacy and tolerability of lovastatin and simvastatin in managing elevated cholesterol levels.
- To assess the safety profile, including adverse effects and potential risks, of these HMG CoA reductase inhibitors.
Main Methods:
- Review of clinical trial data and post-marketing experience with lovastatin and simvastatin.
- Analysis of patient data regarding cholesterol reduction, HDL-cholesterol increase, and adverse event reporting.
Main Results:
- Both drugs demonstrate significant efficacy, reducing total cholesterol by over 30% and LDL-cholesterol by 40%.
- HDL-cholesterol levels increased by approximately 10%. Adverse events led to withdrawal in less than 3% of patients.
- No significant short-term cataractogenic potential was observed. Transaminase elevations occurred in 1-2% of patients and were reversible. Rare cases of myopathy were reported, particularly with concomitant medications.
Conclusions:
- Lovastatin and simvastatin are effective and well-tolerated agents for reducing elevated serum cholesterol.
- Their established safety profile suggests increasing importance in the therapeutic management of hypercholesterolemia and its associated health consequences.